

# 硼替佐米皮下注射方案治疗3例POEMS综合征并文献复习

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2020年03期 页码: 440-443 栏目: 论著(造血器·淋巴系肿瘤) 出版日期: 2019-12-26

**Title:** The successful treatment of 3 patients with POEMS syndrome with subcutaneously injected bortezomib based regimen and literature review

**作者:** 原瑞凤; 纵春涛; 曹春; 杨莉洁; 白庆咸  
空军军医大学第一附属医院血液内科, 陕西 西安 710032

**Author(s):** Yuan Ruifeng; Zong Chuntao; Cao Chun; Yang Lijie; Bai Qingxian  
Department of Hematology, the First Affiliated Hospital of Air Force Medical University, Shaanxi Xi'an 710032, China.

**关键词:** POEMS综合征; 硼替佐米; 皮下注射; 周方案

**Keywords:** POEMS syndrome; bortezomib; subcutaneous injection; weekly plan

**分类号:** R730.5

**DOI:** 10.3969/j.issn.1672-4992.2020.03.019

**文献标识码:** A

**摘要:** 目的: 探讨含硼替佐米方案治疗POEMS综合征的有效性和安全性。方法: 报道3例POEMS综合征经含硼替佐米方案治疗的过程及结果, 并对相关文献进行复习。结果: 3例病人经化疗后1例神经症状得到明显改善, 1例腹胀症状消失, 1例神经症状及胸闷、气短症状改善。结论: 含硼替佐米方案治疗POEMS综合征患者取得了较好疗效, 未出现神经毒副作用。

**Abstract:** Objective: To explore the effectiveness and safety of bortezomib based regimen in the treatment of POEMS syndrome. Methods: The process and results of 3 patients with POEMS syndrome treated with bortezomib based regimen were reported, and relevant literatures were reviewed. Results: After chemotherapy, one patient's neurological symptoms were significantly improved, one patient's abdominal distension disappeared, and one patient's neurological symptoms, chest tightness and shortness of breath were improved. Conclusion: The bortezomib regimen was effective in the treatment of POEMS syndrome without neurotoxic side effects.

## 参考文献/REFERENCES

- [1] Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: Definitions and long-term outcome [J]. Blood, 2003, 101 (7) : 2496-2506.
- [2] ZHU Weiguo, WANG Yu, ZENG Xuejun, et al. A clinical analysis of 32 cases of POEMS syndrome [J]. Chin J Intern Med, 2006, 45(2):108-111. [朱卫国, 王玉, 增学军, 等. POEMS综合征32例临床分析 [J]. 中华内科杂志, 2006, 45(2): 108-111.]
- [3] Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management [J]. Am J Hematol, 2017, 92(8): 814-829.
- [4] Dispenzieri A. POEMS syndrome [J]. Hematology, 2007, 21(6): 285-299.
- [5] Jian L, Dao-bin Z. New advanced in the diagnosis and treatment of POEMS syndrome [J]. Bri J Haematol, 2013, 161(9): 303-315.
- [6] Kourelis TV, Buadi FK, Kumar SK, et al. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience [J]. Am J Hematol, 2016, 91(6): 585-589.
- [7] D' Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome(osteosclerotic myeloma): A single-center experience [J]. Blood, 2012, 120(7): 56-62.
- [8] Blade J, Cibeira MT, Rosinol L. Bortezomib: A valuable new antineoplastic strategy in multiple myeloma [J]. Acta Oncol, 2005, 44(5): 440-448.
- [9] He H, Fu W, Du J, et al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen [J]. Br J Haematol, 2018, 181(1): 122-151.
- [10] Tang X, Shi X, Sun A, et al. Successful bortezomib-based treatment in POEMS syndrome [J]. Eur J Haematol, 2009, 83(6): 609-610.
- [11] Ohguchi H, Ohba R, Onishi Y, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome [J]. Ann Hematol, 2011, 90(9): 1113-1114.

- [12] Li Linghao,Zhang Ri,Tang Xiaowen,et al.A case of POEMS syndrome treated with bortezomib based chemotherapy combined with hematopoietic stem cell transplantation [J] .Chin J Hematol,2011,32(11):733.
- [13] Sobas MA, Alonso Vence N, Diaz Arias J, et al.Efficacy of bortezomib in refractory form of multicentric Castlemans disease associated to poems syndrome(MCD-POEMS variant) [J] .Ann Hematol, 2010, 89(2): 217-219.
- [14] Kaygusuz I, Tezcan H, Cetiner M, et al.Bortezomib: a new therapeutic option for POEMS syndrome [J] .Eur J Haematol, 2010, 84(2): 175-177.
- [15] Warsame R, Kohut IE, Dispenzieri A.Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS [J] .Eur J Haematol, 2012, 88(6): 549-550.
- [16] Wang X, Ye S, Xiong C, et al.Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castlemans disease [J] .Jpn J Clin Oncol, 2011, 41(10): 1221-1224.
- [17] Li J, Zhang W, Kang WY, et al.Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure [J] .Leuk Lymphoma, 2012, 53(12): 2527-2529.
- [18] Zeng Ke,Liu Zhigang,Yang Quanrong,et al.Bortezomib subcutaneous injection combined with autologous hematopoietic stem cell transplantation for poems syndrome: a case report and literature review [J] .Chin J Hematol,2013,34(6):550-552.
- [19] Takehito Iwase, Hirotaka Yokouchi, Sonoko Misawa, et al.Reduction of optic disc oedema by bortezomib and dexamethasone followed by autologous peripheral blood stem cell transplantation in patient with POEMS syndrome [J] .Neuro-ophthalmology, 2018, 42(1): 25-30.
- [20] Yoshimi Ishii, Etsuko Yamazaki, Yasufumi Ishiyama,et al.Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation [J] .Int J Hematol, 2013, 98(6): 723-728.
- [21] Argyriou AA, Iconomou G, Kalofonos HP.Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature [J] .Blood, 2008, 112(5): 1593-1599.
- [22] Brinchen S, Larocca A, Rossi D, et al.Efficacy and safety of once-weekly bortezomib in multiple myeloma patients [J] .Blood, 2010, 116(23): 4745-4753.
- [23] Moreau P, Coiteux V, Hulin C, et al.Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma [J] .Haematologica, 2008, 93(12): 1908-1911.

---

**备注/Memo:** 陕西省自然科学基金基础研究计划 (编号: 2017JM8025)

---

更新日期/Last Update: 1900-01-01